The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...

The Clear Oral Syringes Segment Held the Largest Share in 2024, Accounting for 62.9% of Total Revenues Oral Syringes Market ...

Paul Hudson - Chief Executive Officer Francois-Xavier Roger - Chief Financial Officer Houman Ashrafian - Executive Vice President and Head of Research and Development ...

Additional clinical trials are planned in asthma and chronic obstructive pulmonary disease (COPD ... with a dosing regimen of every six months, which can reduce the burden of treatment and ...

And according to the WHO, COPD is the fourth leading cause of death worldwide ... “WIN378, with its best-in-class potential ...

Black Americans have a higher likelihood of having asthma-COPD overlap syndrome (ACOS) but may not know it. Here’s what you ...

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...